PRA Health Sciences ROA 2013-2018 | PRAH

Current and historical return on assets (ROA) values for PRA Health Sciences (PRAH) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets. PRA Health Sciences ROA for the three months ending September 30, 2018 was 7.48%.
PRA Health Sciences ROA - Return on Assets Historical Data
Date TTM Net Income Total Assets Return on Assets
2018-09-30 $0.07B $3.25B 2.01%
2018-06-30 $0.11B $3.25B 3.42%
2018-03-31 $0.10B $3.28B 3.27%
2017-12-31 $0.09B $3.36B 3.08%
2017-09-30 $0.12B $3.31B 4.62%
2017-06-30 $0.10B $2.41B 4.42%
2017-03-31 $0.11B $2.23B 4.92%
2016-12-31 $0.07B $2.19B 3.08%
2016-09-30 $0.08B $2.22B 3.74%
2016-06-30 $0.08B $2.22B 3.42%
2016-03-31 $0.05B $2.21B 2.20%
2015-12-31 $0.08B $2.23B 3.67%
2015-09-30 $0.03B $2.24B 1.35%
2015-06-30 $0.01B $2.25B 0.31%
2015-03-31 $-0.01B $2.21B -0.40%
2014-12-31 $-0.04B $2.21B -2.09%
2014-09-30 $-0.01B $2.31B -1.11%
2014-06-30 $-0.10B $2.36B -16.42%
2014-03-31 $-0.09B $0.00B inf%
2013-12-31 $-0.08B $0.00B -31.74%
Sector Industry Market Cap Revenue
Medical Medical Services $6.537B $2.259B
PRA Health Sciences, Inc. operates as a global contract research organizations providing outsourced clinical development services to the biotechnology and pharmaceutical industries. It offers therapeutic services in the areas of cardio-metabolic, biosimilars, infectious diseases, immunology, neurology and psychiatry, oncology and hematology, rare diseases, and respiratory needs. The Company engages in bioanalytical laboratory, clinical pharmacology, clinical development, strategic solutions, post marketing research, clinical informatics, clinical diagnostics, and safety and risk management activities. PRA Health Sciences, Inc. is based in Raleigh, North Carolina.
Stock Name Country Market Cap PE Ratio
Express Scripts Holding (ESRX) United States $55.055B 11.38
ICON (ICLR) Ireland $7.186B 22.52
Charles River Laboratories (CRL) United States $6.295B 22.07
HealthEquity (HQY) United States $5.293B 110.78
Premier (PINC) United States $5.276B 17.91
INC Research Holdings (SYNH) United States $5.161B 20.83
Teladoc (TDOC) United States $4.142B 0.00
NovoCure (NVCR) Jersey $2.933B 0.00
AMN Healthcare Services Inc (AMN) United States $2.890B 19.83
BioTelemetry (BEAT) United States $2.126B 37.55
Medpace Holdings (MEDP) United States $1.974B 24.42
Healthways (TVTY) United States $1.472B 18.10
Intrexon (XON) United States $1.393B 0.00
CareDx (CDNA) United States $1.165B 0.00
IKang Healthcare (KANG) China $1.161B 57.65
Natera (NTRA) United States $1.037B 0.00
China Cord Blood (CO) China $0.794B 21.07
Apollo Medical Holdings (AMEH) United States $0.742B 0.00
Surgery Partners (SGRY) United States $0.641B 0.00
Establishment Labs Holdings (ESTA) $0.536B 0.00
Civitas Solutions (CIVI) United States $0.525B 10.34
Interpace Diagnostics (IDXG) United States $0.034B 0.00
Cancer Genetics (CGIX) United States $0.014B 0.00
OpGen (OPGN) United States $0.008B 0.00
FORM Holdings (XSPA) United States $0.005B 0.00
Biocept (BIOC) United States $0.004B 0.00